Júlio Almeidajulioalmeida1994@gmail.comOphthalmology Department, Prof. Doutor Fernando Fonseca Hospital, EPE, Amadora, Portugal

Tomás Costatomasreisdacosta@gmail.comOphthalmology Department, Prof. Doutor Fernando Fonseca Hospital, EPE, Amadora, Portugal

Maria Vivasmariavivastd@gmail.comOphthalmology Department, Prof. Doutor Fernando Fonseca Hospital, EPE, Amadora, Portugal

Catarina Monteirocatarinamimosomonteiro@gmail.comOphthalmology Department, Prof. Doutor Fernando Fonseca Hospital, EPE, Amadora, Portugal

Fernando T. Vazftrancosovaz@gmail.comDepartment of Ophthalmology, Hospital Prof. Doutor Fernando Fonseca, EPE, Amadora, Portugal

Diana Silvadiana_silva1@hotmail.comOphthalmology Department, Prof. Doutor Fernando Fonseca Hospital, EPE, Amadora, Portugal

Cristina Vendrellcvendrell@netcabo.ptOphthalmology Department, Prof. Doutor Fernando Fonseca Hospital, EPE, Amadora, Portugal

Isabel Prietoisabelmcprieto@gmail.comOphthalmology Department, Prof. Doutor Fernando Fonseca Hospital, EPE, Amadora, Portugal

1. Eghrari AO, Riazuddin SA, Gottsch JD. Overview of the cornea: Structure, function, and development. Prog Mol Biol Transl Sci 2015;134:7–23.2. Vaidyanathan U, Hopping GC, Liu HY, Somani AN, Ronquillo YC, Hoopes PC, et al. Persistent corneal epithelial defects: A review article. Med Hypothesis Discov Innov Ophthalmol 2019;8:163–176.

3. Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol 2014;28:168–172.

4. Wilson SE, Medeiros CS, Santhiago MR. Pathophysiology of corneal scarring in persistent epithelial defects after PRK and other corneal injuries. J Refract Surg 2018;34:59–64.

5. NaPier E, Camacho M, McDevitt TF, Sweeney AR. Neurotrophic keratopathy: Current challenges and future prospects. Ann Med 2022;54:666–673.

6. Shtein RM, Shen JF, Kuo AN, Hammersmith KM, Li JY, Weikert MP. Autologous serum-based eye drops for treatment of ocular surface disease: A report by the American Academy of Ophthalmology. Ophthalmology 2020;127:128–133.

7. Diaz-Valle D, Burgos-Blasco B, Gegundez-Fernandez JA, Garcia-Caride S, Puebla-Garcia V, Peña-Urbina P, et al. Topical insulin for refractory persistent corneal epithelial defects. Eur J Ophthalmol 2021;31:2280–2286.

8. Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial. Ophthalmology 2020;127:14–26.

9. Moon HS, Li L, Yoon HJ, Ji YS, Yoon KC. Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea. BMC Ophthalmol 2020;20:147.

10. Titone R, Zhu M, Robertson DM. Insulin mediates de novo nuclear accumulation of the IGF-1/insulin hybrid receptor in corneal epithelial cells. Sci Rep 2018;8(1):1–13.

11. Tong CM, Iovieno A, Yeung SN. Topical insulin for neurotrophic ulcers. Can J Ophthalmol 2020;55:170–172.

12. Galvis V, Niño CA, Tello A, Grice JM, Gómez MA. Insulina tópica en queratopatía neurotrófica tras resección de neurinoma del acústico. Arch Soc Esp Oftalmol (Engl Ed) 2019;94:100–104.

13. Wang AL, Weinlander E, Metcalf BM, Barney NP, Gamm DM, Nehls SM, et al. The use of topical insulin to treat refractory neurotrophic corneal ulcers. Cornea 2017;36:1426–1428.

14. Castro Mora MP, Palacio Varona J, Perez Riaño B, Laverde Cubides C, Rey-Rodriguez DV. Effectiveness of topical insulin for the treatment of surface corneal pathologies. Arch Soc Esp Oftalmol (Engl Ed) 2023;98:220–232.

15. Soares RJ, Arêde C, Sousa Neves F, da Silva Fernandes J, Cunha Ferreira C, Sequeira J. Topical insulin-utility and results in refractory neurotrophic keratopathy in stages 2 and 3. Cornea 2022;41:990–994.

16. Anitua E, de la Fuente M, Sánchez-Ávila RM, de la Sen- Corcuera B, Merayo-Lloves J, Muruzábal F. Beneficial effects of plasma rich in growth factors (PRGF) versus autologous serum and topical insulin in ocular surface cells. Curr Eye Res 2023;48:456–464.

17. Aynsley TR. The use of insulin in the treatment of corneal ulcers. Br J Ophthalmol 1945;29:361–363.

18. Wang AL, Weinlander E, Metcalf BM, Barney NP, Gamm DM, Nehls SM, et al. Use of topical insulin to treat refractory neurotrophic corneal ulcers. Cornea 2017;36:1426–1428.

19. Castro Mora MP, Palacio Varona J, Perez Riaño B, Laverde Cubides C, Rey-Rodriguez DV. Effectiveness of topical insulin for the treatment of surface corneal pathologies. Arch Soc Esp Oftalmol (Engl Ed) 2023;98:220–232.

20. Shtein RM, Shen JF, Kuo AN, Hammersmith KM, Li JY, Weikert MP. Autologous serum-based eye drops for treatment of ocular surface disease: A report by the american academy of ophthalmology. Ophthalmology 2020;127:128–133.

21. Diaz-Valle D, Burgos-Blasco B, Rego-Lorca D, Puebla- Garcia V, Perez-Garcia P, Benitez-Del-Castillo JM, et al. Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea. Acta Ophthalmol 2022;100:e912–9.

22. Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, et al.; REPARO Study Group. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 2018;125:1332–1343.

23. Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial. Ophthalmology 2020;127:14–26.